Results Statistical analyses revealed educated, middle-class African American women who endorse an obligation to show strength/suppress emotions with perceived racial microaggressions experienced increased psychological distress. Conclusion Obligation to show strength/suppress emotion may increase risk for psychological distress among African American women who perceive racial microaggressions. Future research and clinical implications are discussed.Objective Research examining how different dimensions of acculturative beliefs and behaviors influence the risk of biological dysregulation among Latina/os is limited. This study examined associations between three types of acculturation and allostatic load (i.e. a multisystem index of biological dysregulation) across gender and Latina/o ethnic groups. Multiplicative models were also included in order to determine whether immigrant generation moderates acculturation-allostatic load relationships. Design Data were drawn from the Hispanic Community Health Study/ Study of Latina/os. TVB-3166 The sample consisted of 11,841 Latina/os from five ethnic groups Cuban, Puerto Rican, Dominican, Mexican, and South/Central American. The measure for allostatic load was derived from 15 biomarker and anthropometric measures that were designed to capture cardiometabolic risk, glucose metabolism, cardiopulmonary function, inflammation, and organ function. Acculturation measures, immigrant generation, gender, ethnic background, and other covariates were derived from self-reports. Survey corrected ordinary least squares regressions were used to assess relationships between different dimensions of acculturation and allostatic load. Results Results demonstrate dimensions of acculturation play a significant role in the risk of biological dysregulation for Latina/os with divergent results across gender and ethnic background. Estimates from the multiplicative models show immigrant generation moderates acculturation-allostatic load relationships, and relationships are dependent on gender and ethnic background. Conclusion The study contributes to the understanding of how different dimensions of acculturation, as well as other important structural determinants of health, influence the risk of biological dysregulation among Latina/os. Finding from this study can inform targeted strategies designed to reduce the physiological consequences of chronic stress among Latina/os.HIV disproportionately impacts US racial and ethnic minorities but they participate in treatment and vaccine clinical trials at a lower rate than whites. To summarize barriers and facilitators to this participation we conducted a scoping review of the literature guided by the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines. Studies published from January 2007 and September 2019 were reviewed. Thirty-one articles were identified from an initial pool of 325 records using three coders. All records were then assessed for barriers and facilitators and summarized. Results indicate that while racial and ethnic minority participation in these trials has increased over the past 10 years, rates still do not proportionately reflect their burden of HIV infection. While many of the barriers mirror those found in other disease clinical trials (e.g., cancer), HIV stigma is a unique and important barrier to participating in HIV clinical trials. Recommendations to improve recruitment and retention of racial and ethnic minorities include training health care providers on the importance of recruiting diverse participants, creating interdisciplinary research teams that better represent who is being recruited, and providing culturally competent trial designs. Despite the knowledge of how to better recruit racial and ethnic minorities, few interventions have been documented using these strategies. Based on the findings of this review, we recommend that future clinical trials engage community stakeholders in all stages of the research process through community-based participatory research approaches and promote culturally and linguistically appropriate recruitment and retention strategies for marginalized populations overly impacted by HIV.Prior research found low acceptability of HIV treatment as prevention (TasP; or Undetectable = Untransmittable) among HIV-negative men who have sex with men (MSM). This study reports on qualitative data regarding TasP adoption in a sample of 170 self-reported HIV-negative MSM who had engaged in exchange sex (received money, drugs, or other things in exchange for sex). We classified participants along five stages of TasP adoption 1-unaware of TasP (11.2%); 2-aware, but perceived ineffective (17.1%); 3-perceived effective, but unwilling to use (35.3%); 4-willing to rely on TasP, but had never done so (24.1%); and 5-had relied on TasP (12.4%). Obstacles to TasP adoption included the following not believing that it could completely prevent HIV transmission; deeply ingrained fears of HIV/AIDS; concerns about viral load fluctuation; and reluctance to trust a partner’s claimed undetectable status. TasP promotion efforts, which can decrease barriers to HIV testing and HIV stigma, will be more effective if tailored to the obstacles specific to each stage of TasP adoption.Objective To review the use of aripiprazole in children and adolescents. Methods Medline and Embase databases were systematically searched using the keywords aripiprazole and child or adolescent over the period from 2000 to 2019. The initial screen yielded 163 publications, from which 99 studies were reviewed. Results Aripiprazole is one of the most widely prescribed atypical antipsychotics. Like others, its use in children and adolescents is becoming commonplace and occurs in off-label indications. Aripiprazole has proven efficacy for several indications in children and adolescents, including schizophrenia, bipolar disorder, Tourette’s syndrome, and behavioral impairments associated with autism and intellectual disability. Adverse effects are more important in children and adolescents than adults, particularly weight gain, drowsiness, extrapyramidal effects, and metabolic effects, even though the latter may appear less important than with other atypical antipsychotics. Severe adverse effects often occur in multiple-prescription settings.